Oncology
Global

Oncology Experts

Karen Anderson

Associate Professor
Personalized Diagnostics, Piper Center for (PPD)
Arizona State University
United States of America

Karen Anderson

Biography

Dr. Karen Anderson is a tumor biologist who studies how the immune system can be harnessed to detect and alter cancer development. For example, cancer causes the body to produce specific antibodies, which she and her research team can use as biomarkers to detect cancer in early stages of its growth. They use the alterations in immune response to develop new biomarkers for breast, ovarian, pancreatic and HPV-related cancers. Dr. Anderson and her collaborators use molecular techniques, such as in vitro protein arrays, next-gen sequencing, and high-throughput functional genomics, to study early alterations in cancer development. They examine the abnormal characteristics of cancer to identify novel targets for cancer treatment and vaccine development.

Research Interest

The Anderson laboratory is focused on understanding how the immune response can be used to detect and alter cancer development. To create an effective cancer immunotherapy, Dr. Anderson’s team identifies target antigens for vaccine development, and understanding of the mechanisms of immune regulation that limit effective immunotherapy. The lab uses proteomic tools to perform immunoprofiling for cancer and infectious disease detection and monitoring.

Publications

  • Inan, H., Wang, S., Inci, F., Baday, M., Zangar, R., Kesiraju, S., ... Demirci, U. (2017). Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies. Scientific Reports, 7(1), [3322]. DOI: 10.1038/s41598-017-02672-6

  • Dahlstrom, K. R., Anderson, K. S., & Sturgis, E. M. (2017). Human papillomavirus-associated oropharyngeal cancer not just white men anymore. JAMA Oncology, 3(2), 161-162. DOI: 10.1001/jamaoncol.2016.3510

  • Katchman, B. A., Chowell, D., Wallstrom, G., Vitonis, A. F., LaBaer, J., Cramer, D. W., & Anderson, K. S. (2017). Autoantibody biomarkers for the detection of serous ovarian cancer. Gynecologic Oncology, 146(1), 129-136. DOI: 10.1016/j.ygyno.2017.04.005

Global Experts from United States of America

Global Experts in Subject

Share This Profile
Recommended Conferences
View more